Use of vibegron to treat overactive bladder
US12102638B2 · kind B2 · utility
1Cited by
35References
54Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 6, 2018 |
| Grant date | Oct 1, 2024 |
| Priority date | — |
| Expiry date | Mar 22, 2040 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P13/10
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure is directed to a method of treating overactive bladder comprising orally administering to a subject in need thereof an amount of from about 60 mg to about 90 mg (e.g., about 75 mg) of vibegron per day. The present disclosure is also directed to a pharmaceutical unit dosage composition comprising from about 60 mg to about 90 mg (e.g., about 75 mg) of vibegron for oral administration.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.